Brookfield Real Assets Income Fund Inc.
RANYSETrading Snapshot
- Day Range
- $11.45 – $11.65
- 52-Week Range
- $83.41 – $169.70
- Volume
- $2.54B
- Avg Volume
- $3.35B
- Shares Outstanding
- 18.33B
- Next Earnings
- Nov 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $78M
- Last Q Revenue
- $41M
- P/E Ratio
- 42.7
- P/S Ratio
- 12.3x
- EPS (TTM)
- $2.42
- Dividend Yield
- 3.86%
- Dilution (1yr)
- +0.0%
Why Investors Own RA
- ✓High-growth profile — revenue up -6.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Brookfield Real Assets Income Fund Inc.
RA
StockOtter · stockotter.spaceAbout Brookfield Real Assets Income Fund Inc.
A company profile for Brookfield Real Assets Income Fund Inc. isn’t available yet — check back soon.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw
Brookfield Real Assets Income Fund (NYSE:RA) Stock Sale Disclosed by Rep. Kevin Hern
Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Brookfield Real Assets Income Fund Inc. (NYSE: RA). In a filing disclosed on September 25th, the Representative disclosed that they had sold between
Brookfield Real Assets Income Fund Inc. Declares Q4 2026 Distribution Schedule
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund's monthly distributions for October
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR
Short Interest in Brookfield Real Assets Income Fund Inc. (NYSE:RA) Drops By 36.8%
Brookfield Real Assets Income Fund Inc. (NYSE: RA - Get Free Report) was the target of a large decrease in short interest in August. As of August 14th, there was short interest totaling 56,549 shares, a decrease of 36.8%
LAPIX Therapeutics Appoints Nimbus CEO Abbas Kazimi to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist program through Phas